<DOC>
	<DOC>NCT01449591</DOC>
	<brief_summary>This study will evaluate the safety, tolerability and efficacy of BFH772 after 12 weeks of treatment as compared to an active control and vehicle in patients with erythemato-telangiectatic rosacea.</brief_summary>
	<brief_title>Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<criteria>Have persistent facial erythema on the cheeks of at least moderate severity. Women must not be able to bear children Have more than 12 inflammatory lesions on the face Previous treatment of facial skin with lasers or electrocauterisation within 2 months prior to entering the study Have facial hair that makes it difficult to evaluate rosacea on the face Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>BFH772</keyword>
	<keyword>rosacea</keyword>
	<keyword>erythemato-telangiectatic rosacea</keyword>
</DOC>